What did the patient actually die of?

Two questions that come up regularly are whether: (a) men who are said to have died of prostate cancer actually did, and (b) men with prostate cancer who are said to have died of something else actually died of their prostate cancer. … READ MORE …

Men initially diagnosed with de novo metastatic prostate cancer are living longer

A newly published study entitled “Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study” is important … but needs to be interpreted with a significant degree of caution. … READ MORE …

Contemporary rates of overall and prostate cancer-specific mortality in Norway

A newly published study in the journal Urology (“the Gold journal”) has reported data on risk of death from prostate cancer and other causes among > 3,000 contemporary patients diagnosed with non-metastatic prostate cancer in 2004-2005. … READ MORE …

Statin therapy lowers mortality rates among Danish prostate cancer patients

According to a media release and a presentation given at the European Association of Urology (EAU) in Europe this week, statin therapy has a small but significant impact on overall and prostate cancer-specific mortality rates. … READ MORE …

Does regular anticoagulant therapy really reduce risk of prostate cancer mortality?

A study based on the CaPSURE database, and just published in the Journal of Oncology, has again suggested that prostate cancer patients who are regular users of anticoagulant are a lower risk of prostate cancer-specific mortality than non-aspirin users. … READ MORE …

Who needs aggressive treatment after initial radiation … and who does not?

A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality. … READ MORE …

Prolaris: prognostically accurate but of limited utility?

According to a media release from  Myriad Genetics, the company’s investigational genetic test (Prolaris™) can accurately predict prostate cancer-specific mortality at 10 years in men known to have clinically localized prostate cancer. … READ MORE …